In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Related to this article
Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress
The European Commission has approved epcoritamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma.
The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.
IV ST-001 nanoFenretinide produced a 28% response rate in heavily pretreated cutaneous T-cell lymphoma in a first-in-human phase 1a trial.
The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.
The FDA approved Orca-T for use in matched donor HSCT with a myeloablative preparative regimen in hematological malignancies.
Both annamycin-containing arms produced numerically higher CR and CRc rates vs cytarabine alone in relapsed/refractory AML.
Advertisement
Advertisement
Trending on OncLive
1
GE HealthCare and Mayo Clinic Aim to Advance Personalized Cancer Treatment Through New Theranostics Research Collaboration
2
Dr Davids on the Significance of Efficacy Data for Pirtobrutinib Plus VR in R/R CLL
3
Dr Ho on a Phase 3 Trial Evaluating Oz-V in Unresectable, Recurrent or Metastatic OSPCC
4
Dr Ravi on the Background and Rationale of the Phase 4 PSMAtrack Study in mHSPC
5